Rikke Kruse1,2,3, Sara G Vienberg4, Birgitte F Vind3, Birgitte Andersen4, Kurt Højlund5,6,7. 1. Department of Clinical Research, Section of Molecular Diabetes and Metabolism, University of Southern Denmark, Odense, Denmark. 2. Department of Molecular Medicine, Section of Molecular Diabetes and Metabolism, University of Southern Denmark, Odense, Denmark. 3. Department of Endocrinology, Odense University Hospital, Kløvervænget 6, DK-5000, Odense, Denmark. 4. Diabetes Research Unit, Novo A/S, Måløv, Denmark. 5. Department of Clinical Research, Section of Molecular Diabetes and Metabolism, University of Southern Denmark, Odense, Denmark. kurt.hoejlund@rsyd.dk. 6. Department of Molecular Medicine, Section of Molecular Diabetes and Metabolism, University of Southern Denmark, Odense, Denmark. kurt.hoejlund@rsyd.dk. 7. Department of Endocrinology, Odense University Hospital, Kløvervænget 6, DK-5000, Odense, Denmark. kurt.hoejlund@rsyd.dk.
Abstract
AIMS/HYPOTHESIS: Pharmacological doses of FGF21 improve glucose tolerance, lipid metabolism and energy expenditure in rodents. Induced expression and secretion of FGF21 from muscle may increase browning of white adipose tissue (WAT) in a myokine-like manner. Recent studies have reported that insulin and exercise increase FGF21 in plasma. Obesity and type 2 diabetes are potentially FGF21-resistant states, but to what extent FGF21 responses to insulin and exercise training are preserved, and whether FGF21, its receptors and target genes are altered, remains to be established. METHODS: The effects of insulin during euglycaemic-hyperinsulinaemic clamps and 10 week endurance training on serum FGF21 were examined in individuals with type 2 diabetes and in glucose tolerant overweight/obese and lean individuals. Gene expression of FGF21, its receptors and target genes in muscle and WAT biopsies was evaluated by quantitative real-time PCR (qPCR). RESULTS: Insulin increased serum and muscle FGF21 independent of overweight/obesity or type 2 diabetes, and there were no effects associated with exercise training. The insulin-induced increases in serum FGF21 and muscle FGF21 expression correlated tightly (p < 0.001). In WAT, overweight/obesity with and without type 2 diabetes led to reduced expression of KLB, but increased FGFR1c expression. However, the expression of most FGF21 target genes was unaltered except for reduced CIDEA expression in individuals with type 2 diabetes. CONCLUSIONS/ INTERPRETATION: Insulin-induced expression of muscle FGF21 correlates strongly with a rise in serum FGF21, and this response appears intact in overweight/obesity and type 2 diabetes. FGF21 resistance may involve reduced KLB expression in WAT. However, increased FGFR1c expression or other mechanisms seem to ensure adequate expression of most FGF21 target genes in WAT.
AIMS/HYPOTHESIS: Pharmacological doses of FGF21 improve glucose tolerance, lipid metabolism and energy expenditure in rodents. Induced expression and secretion of FGF21 from muscle may increase browning of white adipose tissue (WAT) in a myokine-like manner. Recent studies have reported that insulin and exercise increase FGF21 in plasma. Obesity and type 2 diabetes are potentially FGF21-resistant states, but to what extent FGF21 responses to insulin and exercise training are preserved, and whether FGF21, its receptors and target genes are altered, remains to be established. METHODS: The effects of insulin during euglycaemic-hyperinsulinaemic clamps and 10 week endurance training on serum FGF21 were examined in individuals with type 2 diabetes and in glucose tolerant overweight/obese and lean individuals. Gene expression of FGF21, its receptors and target genes in muscle and WAT biopsies was evaluated by quantitative real-time PCR (qPCR). RESULTS:Insulin increased serum and muscle FGF21 independent of overweight/obesity or type 2 diabetes, and there were no effects associated with exercise training. The insulin-induced increases in serum FGF21 and muscle FGF21 expression correlated tightly (p < 0.001). In WAT, overweight/obesity with and without type 2 diabetes led to reduced expression of KLB, but increased FGFR1c expression. However, the expression of most FGF21 target genes was unaltered except for reduced CIDEA expression in individuals with type 2 diabetes. CONCLUSIONS/ INTERPRETATION:Insulin-induced expression of muscle FGF21 correlates strongly with a rise in serum FGF21, and this response appears intact in overweight/obesity and type 2 diabetes. FGF21 resistance may involve reduced KLB expression in WAT. However, increased FGFR1c expression or other mechanisms seem to ensure adequate expression of most FGF21 target genes in WAT.
Authors: Fredirick L Mashili; Reginald L Austin; Atul S Deshmukh; Tomas Fritz; Kenneth Caidahl; Katrin Bergdahl; Juleen R Zierath; Alexander V Chibalin; David E Moller; Alexei Kharitonenkov; Anna Krook Journal: Diabetes Metab Res Rev Date: 2011-03 Impact factor: 4.876
Authors: Elisabet Arvidsson Nordström; Mikael Rydén; Emma C Backlund; Ingrid Dahlman; Maria Kaaman; Lennart Blomqvist; Barbara Cannon; Jan Nedergaard; Peter Arner Journal: Diabetes Date: 2005-06 Impact factor: 9.461
Authors: Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu Journal: Diabetes Date: 2008-02-05 Impact factor: 9.461
Authors: Alberto O Chavez; Marjorie Molina-Carrion; Muhammad A Abdul-Ghani; Franco Folli; Ralph A Defronzo; Devjit Tripathy Journal: Diabetes Care Date: 2009-06-01 Impact factor: 19.112
Authors: Salah Sommakia; Naredos H Almaw; Sandra H Lee; Dinesh K A Ramadurai; Iosif Taleb; Christos P Kyriakopoulos; Chris J Stubben; Jing Ling; Robert A Campbell; Rami A Alharethi; William T Caine; Sutip Navankasattusas; Guillaume L Hoareau; Anu E Abraham; James C Fang; Craig H Selzman; Stavros G Drakos; Dipayan Chaudhuri Journal: Circ Heart Fail Date: 2021-12-06 Impact factor: 8.790
Authors: Rugivan Sabaratnam; Andreas J T Pedersen; Jonas M Kristensen; Aase Handberg; Jørgen F P Wojtaszewski; Kurt Højlund Journal: Physiol Rep Date: 2018-06